About the Event
Each year as many as 15,000 babies in the U.S. develop Bronchopulmonary Dysplasia (BPD), a condition that is the leading cause of death in premature infants.
AyuVis is a biopharmaceutical company dedicated to helping pre-term babies grow into normal, healthy adults. They have developed a first-in-class small molecule treatment for BPD that has shown great promise in pre-clinical testing and has been granted Orphan Drug Status by the FDA. The company has completed the Pre-IND meeting and is in the process of its Phase 1 filing.
Please join our webinar to hear from AyuVis founder and CEO, Dr. Suchi Acharya, who will talk about the dire need for this treatment and the rapid progress that’s being made in saving the lives of these most vulnerable babies.